Abstract:BackgroundHomocysteine is an intermediate metabolite implicated in the risk of placenta-mediated complications, including preeclampsia, placental abruption, fetal growth restriction, and pregnancy loss. Large cohort and case-control studies have reported inconsistent associations between homocysteine and these complications. The purpose of this study was to investigate whether elevated maternal plasma homocysteine concentration in the early to mid-second trimester is associated with an increased risk of placenta-mediated complications. We examined the following potential moderating factors that may explain discrepancies among previous studies: high-risk pregnancy and the MTHFR 677C>T polymorphism.MethodsWe analyzed data from participants recruited to the Ottawa and Kingston (OaK) Birth Cohort from 2002 to 2009 in Ottawa and Kingston, Canada. The primary outcome was a composite of any placenta-mediated complication, defined as a composite of small for gestational age (SGA) infant, preeclampsia, placental abruption, and pregnancy loss. Secondary outcomes were, individually: SGA infant, preeclampsia, placental abruption, and pregnancy loss. We conducted multivariable logistic regression analyses with homocysteine as the primary continuous exposure, adjusting for gestational age at the time of bloodwork and explanatory maternal characteristics. The functional form, i.e., the shape of the homocysteine association with the outcome was examined using restricted cubic splines and information criteria (Akaike’s/Bayesian Information Criterion statistics). Missing data were handled with multiple imputation.Results7587 cohort participants were included in the study. Maternal plasma homocysteine concentration was significantly associated (linearly) with an increased risk of both the composite outcome of any placenta-mediated complication (p = 0.0007), SGA (p = 0.0010), severe SGA, and marginally with severe preeclampsia, but not preeclampsia, placental abruption and pregnancy loss. An increase in homocysteine concentration significantly increased the odds of any placenta-mediated complication (odds ratio (OR) for a 5 μmol/L increase: 1.63, 95% Confidence Interval (CI) 1.23–2.16) and SGA (OR 1.76, 95% CI 1.25–2.46). Subgroup analyses indicated some potential for modifying effects of the MTHFR 677C>T genotype and high-risk pregnancy, although the interaction was not statistically significant (high-risk subgroup OR 2.37, 95% CI 1.24–4.53, p-value for interaction =0.14).ConclusionsOur results suggest an independent effect of early to mid-pregnancy elevated maternal homocysteine on placenta-mediated pregnancy complications.

Maternal exposure to folic acid antagonists and placenta-mediated adverse pregnancy outcomes

Maternal body mass index and the association between folic acid supplements and neural tube defects.

Maternal exposure to folate antagonists and susceptibility to congenital heart disease in offspring: A systematic review and meta‐analysis

Preventive Effects of Folic Acid Supplementation on Adverse Maternal and Fetal Outcomes

Maternal folic acid supplementation to prevent preeclampsia: a systematic review and meta-analysis.

Pre-conceptional Intake of Folic Acid Supplements is Inversely Associated with Risk of Preterm Birth and Small-for-gestational-age Birth: a Prospective Cohort Study

Folic acid is positively associated with uteroplacental vascular resistance: the Generation R study

Maternal and neonatal outcomes after exposure to ADHD medication during pregnancy: A systematic review and meta-analysis

Influence of different forms of folic acid supplementation on pregnancy outcomes under various exposure factors

Folic Acid Levels During Pregnancy Regulate Trophoblast Invasive Behavior and the Possible Development of Preeclampsia

Maternal folate status and placental vascular malperfusion: Findings from a high-risk US minority birth cohort

Folic Acid and Multivitamin Supplement Use and Risk of Placental Abruption: A Population-Based Registry Study

Maternal folate, one-carbon metabolism and pregnancy outcomes

Folic acid supplementation during early pregnancy and the risk of gestational hypertension and preeclampsia.

Placenta-Related Parameters at Delivery in Relation to Folic Acid Supplementation in Different Pregnancies

Folic acid: The key to a healthy pregnancy - A prospective study on fetomaternal outcome

Initiation and duration of folic acid supplementation in preventing congenital malformations

Folic acid and multivitamin supplement use and risk of placental abruption: a population-based registry study.

Risk of Excess Maternal Folic Acid Supplementation in Offspring

The role of maternal homocysteine concentration in placenta-mediated complications: findings from the Ottawa and Kingston birth cohort

Maternal Periconceptional Folic Acid Supplementation and Risk for Fetal Congenital Genitourinary System Defects.